TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06199674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation therapy
Description: Patients in the PBM group will be delivered a portable PBM device (PBM Healing Ortho) at the beginning of orthodontic treatment and will be instructed to use it daily at home for 8 minutes (4 min per arch) after tooth brushing.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: orthodontic fixed-appliance
Description: All eligible patients will receive orthodontic treatment with a pre-adjusted fixed appliance (0.022'' × 0.028'' slot system, MBT, 3M Unitek) provided by the same practitioner. At the start of treatment, a cantilever auxiliary arch bent with a 0.017'' × 0.025'' Stainless Steel wire (3M Unitek) will be used to apply a 100 g intrusion force to the premolars that will be extracted in 3 months. All other teeth will undergo regular orthodontic treatment with a standard archwire protocol (0.014'' NiTi, 0.016'' NiTi, 0.018'' NiTi, 0.017'' × 0.025'' NiTi, 0.019'' × 0.025'' NiTi, and 0.019'' × 0.025'' SS, 0.019'' × 0.025'' TMA) for alignment, leveling, space closure, detailing, and finishing. For en masse retraction, a 150 g force will be applied by coil springs, allowing bracket slots to slide along the 0.019'' × 0.025'' SS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthodontic fixed-appliance
Description: All eligible patients will receive orthodontic treatment with a pre-adjusted fixed appliance (0.022'' × 0.028'' slot system, MBT, 3M Unitek) provided by the same practitioner. At the start of treatment, a cantilever auxiliary arch bent with a 0.017'' × 0.025'' Stainless Steel wire (3M Unitek) will be used to apply a 100 g intrusion force to the premolars that will be extracted in 3 months. All other teeth will undergo regular orthodontic treatment with a standard archwire protocol (0.014'' NiTi, 0.016'' NiTi, 0.018'' NiTi, 0.017'' × 0.025'' NiTi, 0.019'' × 0.025'' NiTi, and 0.019'' × 0.025'' SS, 0.019'' × 0.025'' TMA) for alignment, leveling, space closure, detailing, and finishing. For en masse retraction, a 150 g force will be applied by coil springs, allowing bracket slots to slide along the 0.019'' × 0.025'' SS.
Study: NCT05420844

Intervention type: OTHER
Group type: OTHER
Intervention: Kintsugi voice journaling application
Description: Participants will use the Kintsugi voice journaling phone application for three months.
Study: NCT05692479

Intervention type: OTHER
Intervention: Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data
Description: Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data
Study: NCT06171581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball
Description: In the study, the experimental group was given a round, compressible ball for stress ball application and it was planned to squeeze this ball in their hands as often as they wanted during anaesthesia and endometrial biopsy application. The endometrial biopsy procedure is a procedure that usually takes between 8-10 minutes. The results will be evaluated considering these average times. As it is foreseen that individuals may experience the most intense anxiety and stress during anaesthesia and biopsy, it was preferred to cover this time period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: In the study, the no intervention group ( control group) will receive no intervention and blood pressure and stress measurements will be made with routine care and nursing interventions.
Study: NCT05729607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical soft tissue augmentation
Description: Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical soft tissue augmentation
Description: Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
Study: NCT05004051

Intervention type: DEVICE
Intervention: ViTAA Analysis
Description: Imaging Analysis Software

Intervention type: DEVICE
Intervention: ViTAA Analysis
Description: Imaging Analysis Software
Study: NCT05040984

Intervention type: DRUG
Intervention: Solifenacin Oral Tablet
Description: Solifenacin 1 tablet per day

Intervention type: DRUG
Intervention: Mirabegron 25mg
Description: Mirabegron 1 tablet per day
Study: NCT05249829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.529
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection
Study: NCT04990479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAd-PEV
Description: Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAd-PEV
Description: Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAd-PEV
Description: Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-PEV
Description: Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-PEV
Description: Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-PEV
Description: Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).
Study: NCT06414187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-Aortic Balloon Pump
Description: Patients who are randomized to the IABP-arm will be supported with IABP according to local, clinical guidelines (including algorithms for anticoagulation, verification of correct positioning and weaning strategies). The IABP console and disposables should be used according to the instructions for use, including the use of an appropriate-sized IABP balloon alligned with patient length and height.
Study: NCT05639660

Intervention type: OTHER
Intervention: non-interventional
Description: The treatment guideline recommends the 3+Q2m regimen for Aflibercept, but this study is an observational study, no intervention is made in the subjects' treatment regimen. There is no prescribed visit plan. According to the decision of the doctor and the patient according to the treatment plan, the patient needs to come to the clinic within the prescribed time window (3, 6, and 12 months) to facilitate the recording of data.
Study: NCT05007808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G001 Topical Gel
Description: Non-steroidal anti-inflammatory drug for topical administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Gel for topical administration
Study: NCT06299085

Intervention type: OTHER
Group type: OTHER
Intervention: 50 adult patients suffering from severe or morbid obesity, male and female, candidates for bariatric surgery.
Description: 50 adult patients suffering from severe or morbid obesity (BMI ≥ 35 kg/m2 in the presence of comorbidities and BMI ≥ 40 kg/m2, respectively), male and female, candidates for bariatric surgery (Sleeve Gastrectomy and Roux-en-Y Gastric Bypass).~Two timepoints: T0 (pre-hospitalization) and T1 (follow-up 12 months +/- 1 month).~Expected assessments at T0 and T1:~* Blood chemistry tests to monitor metabolic markers involved in dietary and metabolic changes.~* Bone densitometry for body composition analysis (DEXA).~* Analysis of pre-intervention walking and the ability to recover motor activity after bariatric surgery using gait analysis.
Study: NCT04822597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Description: Lidocaine is a local anesthetic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Description: Lidocaine is a local anesthetic.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy(R)
Description: Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.
Study: NCT06239675

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS
Study: NCT04822597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy(R)
Description: Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack
Description: Ice cools the skin and can provide some numbing for pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice pack
Description: Ice cools the skin and can provide some numbing for pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack
Description: Ice cools the skin and can provide some numbing for pain.
Study: NCT05414487

Intervention type: DRUG
Intervention: Ofatumumab
Description: There is no treatment allocation. Patients with MS or NMOSD administered Ofatumumab by prescription will be enrolled. Participants will receive 20mg ofatumumab (20 mg/0.4 ml) by subcutaneous injection. Ofatumumab is administrated at baseline, Day 7, Day 14 and monthly thereafter until the end of the study.
Study: NCT05880615

Intervention type: OTHER
Intervention: collection of datas
Description: collection of datas:~* Post-operative occurrence (within the first 48 hours after extubation) of post-operative delirium via the CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) scale result~* Post-operative hypoxemia defined as a PaO2/FiO2 ratio \< 300 in the first 48 hours after extubation~* reflex ileus defined as the absence of gas and/or matter in the first 48 hours after extubation,~* total morphine consumption in the first 48 hours after surgery~* pain at 24 hours and 48 hours after surgery~* post-operative nausea and vomiting, major complications (neurological, respiratory, cardiac, infectious)~* mortality 30 days after surgery

Intervention type: OTHER
Intervention: collection of datas
Description: collection of datas:~* Post-operative occurrence (within the first 48 hours after extubation) of post-operative delirium via the CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) scale result~* Post-operative hypoxemia defined as a PaO2/FiO2 ratio \< 300 in the first 48 hours after extubation~* reflex ileus defined as the absence of gas and/or matter in the first 48 hours after extubation,~* total morphine consumption in the first 48 hours after surgery~* pain at 24 hours and 48 hours after surgery~* post-operative nausea and vomiting, major complications (neurological, respiratory, cardiac, infectious)~* mortality 30 days after surgery
Study: NCT04647812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted rehabilitation
Description: Augmented exercise therapy with novel technology and home-based telerehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: Traditional multidisciplinary in-patient rehabilitation
Study: NCT05879549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed Chain Exercise Group
Description: Closed Chain Exercise Group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Exercise Group
Description: Proprioceptive Exercise Group
Study: NCT04949360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive-Behavioral Therapy for Insomnia and complementary therapies
Description: The CBTi-O and CBTi-O+ interventions are based on real life user experience. The users will have access to different versions of the platform. The intervention will last eitght weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive-Behavioral Therapy for Insomnia and complementary therapies
Description: The CBTi-O and CBTi-O+ interventions are based on real life user experience. The users will have access to different versions of the platform. The intervention will last eitght weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Cognitive Behavioural Therapy for Insomnia
Description: This is the gold standard behavioral treatment for insomnia and will be performed by independent board-certified sleep psychologists. The treatments will last eight weeks and the appointments will be made by video-calls.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep hygiene - minimal intervention
Description: It is composed by educational material about normal sleep pattern and sleep hygiene. It will be delivered by regular mail and email.
Study: NCT06004011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARROW strategies
Description: ARROW strategies are peer-to-peer support at the patient, provider and health system levels

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-time education
Description: The comparison group will receive a one-time education campaign that will provide informational brochures to adolescents and young adults living with HIV and HIV providers
Study: NCT06304974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Administration by intravenous infusion
Study: NCT05008861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsulized Fecal Microbiota Transplant
Description: Capsules contained washed fecal microbiota.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody
Description: Standard dose of one of anti-PD-1/PD-L1 mAbs administered as a 1 hour infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Standard dose of Platinum based Chemotherapy every 3 weeks.
Study: NCT05448781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatin
Description: Eligible patients with advanced NSCLC were treated with endostatin combined with Tirelizumab and platinum-containing two-drug chemotherapy.26 cases of non-squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Pemetrexed+Carboplatin. and 12 cases of squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Paclitaxel/Albumin paclitaxel+Carboplatin,The maintenance treatment phase was continuous treatment with Endu combined with Tirelizumab
Study: NCT05021094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuntai Capsule
Description: The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuntai Capsule
Description: The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuntai Capsule
Description: The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoston
Description: The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoston
Description: The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.
Study: NCT04824053

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conventional milk
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conventional yogurt
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conventional fresh cheese
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months
Study: NCT06486207

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gong's mobilization
Description: increases the range of motion for shoulder medial rotation by allowing shoulder medial rotation with the humeral head in a normal position against the glenoid cavity of the scapula

Intervention type: OTHER
Group type: OTHER
Intervention: Kendall Exercise
Description: The Kendall exercise methods were as follows: Strengthening the deep cervical flexors, lying flat on the back with the chin down and then lifting the head and holding this position for 2-8 seconds to strengthen deep cervical flexors
Study: NCT05500443

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (Menaquinone-7)
Description: Oral supplementation with vitamin K2 (Menaquinone-7 (MK-7)) 720 µg/day and D 25 µg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin K2 (Menaquinone-7)
Description: Oral supplementation with vitamin K2 (Menaquinone-7 (MK-7)) 720 µg/day and D 25 µg/day
Study: NCT05066737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral suspension via V-NOTES surgery
Description: pop-q, pisq-12 assesment of patients with pelvic organ prolapse before and 6 or 12 month after lateral suspension surgery performed via V-NOTES technique.
Study: NCT05877313

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water foot bath
Description: Participants will use the same foot bath and sterile water used in the treatment arm minus the active ingredients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Participants will use a foot bath filled with 500mL of NORS for 15 min. The solution's two components are mixed 1:1 to 500mL in the foot bath immediately before treatment. The solution contains NO at 68.9ppm\*hrs and 203.2ppm\*hrs for 1X and 2X solutions respectively, and it acts as a virucidal agent. Instructions for storage, handling, and use will be provided to site staff and participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Participants will use a foot bath filled with 500mL of NORS for 15 min. The solution's two components are mixed 1:1 to 500mL in the foot bath immediately before treatment. The solution contains NO at 68.9ppm\*hrs and 203.2ppm\*hrs for 1X and 2X solutions respectively, and it acts as a virucidal agent. Instructions for storage, handling, and use will be provided to site staff and participants.